Early Metformin Treatment in a SHANK3 Mouse Model
In a recent preclinical study, researchers at McGill University found that metformin (an FDA-approved treatment for type 2 diabetes) improved behavior…
NNZ-2591 Phase 2 Publication
By Lauren Schmitt, PhDJanuary 12, 2026With Neuren's Phase 3 clinical trial for NNZ-2591 now open for enrollment, the recent publication of…
Registration Is Open: What to Know About the 2026 PMSF Family Conference
Registration is officially open for the 2026 PMSF Family Conference, The Climb We Make Together, Presented by Neuren Pharmaceuticals, and we’re…
Why Sharing Clinical Trial Experiences Can Harm Research
By: Lauren Schmitt, PhD, Chief Science Officer, PMSFDate: December 22, 2025 How Families Can Help Protect the Path to New Treatments…
Why Nutrition Matters in Phelan-McDermid Syndrome
Why Nutrition Matters in Phelan-McDermid Syndrome By: Meagan Hutchinson, Science & Research Administrator, Phelan-McDermid Syndrome FoundationDecember 18, 2025Nutrition plays a critical…
Together We Are Mighty: Attending the 2025 NORD Breakthrough Summit
Together We Are Mighty: Attending the 2025 NORD Breakthrough Summit By: Meagan Hutchinson This week, I had the privilege of attending…
Driving Research Breakthroughs
Driving Research Breakthroughs Funding research, treatments, and cures for Phelan-McDermid SyndromeThe Phelan-McDermid Syndrome Foundation is proud to launch Driving Research Breakthroughs,…
SPACES Webinar Series Recap: Understanding Catatonia in Autism
SPACES Webinar Series Recap: Understanding Catatonia in Autism By Meagan HutchinsonPhelan-McDermid Syndrome Foundation proudly co-sponsored the six-part "Supporting People with Autism…
Gene Therapy 101 Webinar Recap
In June, the Phelan-McDermid Syndrome Foundation hosted a webinar in collaboration with the American Society of Gene & Cell Therapy (ASGCT).…
2025 Shannon O’Boyle Memorial Grant Awardee
We have exciting news to share with our Phelan-McDermid syndrome community! This year’s PMSF research grant will help drive groundbreaking science…